CAR-T cell therapy for recurrent glioblastoma brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new treatment called CAR-T cell therapy for people whose glioblastoma (a type of brain tumor) has come back or not responded to standard care. The treatment uses your own immune cells (T cells) that are specially modified to attack tumor cells that show a marker called CD276.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain tumor called glioblastoma that is confirmed by a biopsy.
- Your cancer must have come back or gotten worse after standard treatment, and surgery is not an option.
- You must be 18 years or older and expected to live more than 2 months.
- Your tumor sample must show a specific protein called CD276 (this is checked with a test on your tumor tissue).
- You need to be in fairly good overall health, able to do daily activities, and have your heart, liver, kidneys, and blood counts within safe limits.
- You cannot be taking strong medicines that suppress your immune system, have certain infections, or have other health conditions that might make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
Hear when a new Recurrent or Progressive Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.